Health and Fitness Health and Fitness
Fri, September 28, 2012
[ Fri, Sep 28th 2012 ] - Market Wire
call for signatures
Thu, September 27, 2012

Baxter Appoints Two New Directors to Its Board


Published on 2012-09-27 13:31:08 - Market Wire
  Print publication without navigation


DEERFIELD, Ill.--([ ])--Baxter International Inc. (NYSE:BAX) today announced it has appointed two new members to its Board of Directors, Uma Chowdhry, PhD, and Thomas F. Chen. The appointments are effective November 2012.

Chowdhry most recently served as Senior Vice President and Chief Science and Technology Officer at E.I. du Pont de Nemours before retiring in 2010. She started her career at DuPont in 1977 as a research scientist and held positions of increasing responsibility. Chowdhry holds a bacheloras of science degree in physics and math from Mumbai University, a masteras degree in engineering science from California Institute of Technology and a PhD in materials science from Massachusetts Institute of Technology.

Chen most recently served as Senior Vice President, International Nutrition, at Abbott before retiring in 2010. During his Abbott career, he served in a number of roles of increasing responsibility, primarily in Pacific/Asia/Africa where he oversaw expansion into a number of emerging markets. Chen started his career with American Cyanamid in 1979 and earned a bacheloras degree in international business from National Cheng Chi University in Taipei, and a masteras in business administration from Indiana University.

''The appointments of Uma and Thomas deepen the strength of the Baxter Board of Directors and align with our history of scientific and product innovation, and our international presence as a company,'' said Robert L. Parkinson, Jr., Baxteras Chairman and Chief Executive Officer.

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

Contributing Sources